News

Filter

Tag: Timothy Miller

October 9, 2023
Avidan, England, Miller elected to National Academy of Medicine
Membership is one of highest U.S. honors in health and medicine.
News Release
April 25, 2023
Drug for rare form of ALS, based in part on WashU research, approved by FDA
Washington University neurologist led international trials of the drug, tofersen.
News Release, Video
February 2, 2023
Miller receives Rainwater Prize for Brain Research
Honored for work developing new kind of therapy for neurodegenerative diseases.
National Leaders
September 21, 2022
Investigational drug for genetic form of ALS improves disease’s molecular signs
Extended use of tofersen may help stabilize muscle strength, control.
News Release
July 8, 2020
Experimental drug shows early promise against inherited form of ALS, trial indicates
Phase 1/phase 2 trial shows evidence for safety, biological activity of tofersen; phase 3 trial underway.
News Release
January 6, 2020
Miller receives international innovation prize
Recognized for developing experimental treatment for ALS.
National Leaders
August 15, 2019
Antisense drugs for Huntington’s, ALS and prion diseases could meet the dire need for brain treatments
Source: Scientific American
May 1, 2019
Experimental ALS treatment could be ‘game-changing’ for genetic ALS
Source: CNN
July 16, 2018
New ALS therapy in clinical trials
Drug extends survival, reverses some neuromuscular damage in animals.
News Release
May 7, 2018
Miller receives Essey award from neurological society
Recognized for advancing research into ALS.
National Leaders
December 4, 2017
Pursuing a precision paradigm
Medical school experts describe the move from current standards of care to a more personalized approach to treatment.
Source: Washington Magazine
January 25, 2017
Drug compound halts Alzheimer’s-related damage in mice
Appears to reverse some neurological harm.
News Release